Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Abbott Incomes Drops 40% In 3Q

October 20, 2010 6:51 am | News | Comments

Drug and medical device maker Abbott Laboratories said its third-quarter net income dropped 40 percent on costs connected with its purchase of Belgian drugmaker Solvay Pharmaceuticals and its recall of the diabetes drug Meridia.

TOPICS:

Can iPS Cells Reprogram Disease Modeling?

October 20, 2010 6:16 am | by Don O’Neil, Director of Marketing, Cell Biology, EMD Millipore | Articles | Comments

The ability to reprogram adult somatic cells into induced pluripotent stem cells has created tremendous interest and excitement since they were first generated from mouse and human fibroblasts several years ago.

TOPICS:

Study Combines Therapies to Attack the Viral Reservoir of HIV Patients

October 19, 2010 9:09 am | News | Comments

Cytheris SA announced the initiation of Phase II clinical trial of the company’s investigative immunomodulatory agent CYT107 in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir and the CCR5 inhibitor, maraviroc.

TOPICS:
Advertisement

EMA Opinion Paves Way for Pixuvri MAA Submission

October 19, 2010 8:56 am | News | Comments

The Pediatric Committee of the European Medicines Agency has adopted an opinion agreeing to Cell Therapeutics, Inc.'s Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan (PIP) for the treatment of lymphoid malignancies and solid tumors in children between ages of 6 months and 18 years.

TOPICS:

Allergy Drug Clears Condition, Not Symptoms of Throat Disease

October 19, 2010 8:48 am | News | Comments

Research from the first controlled trial of swallowed fluticasone nasal spray (Flonase) on people with eosinophilic esophagitis showed that the aerosolized swallowed allergy drug helped treat the cause of the throat condition, but symptoms lingered.

TOPICS:

Charles River Licenses Knockout Rat Models

October 19, 2010 8:41 am | News | Comments

Charles River Laboratories International, Inc. has entered into an agreement with Transposagen Biopharmaceuticals, Inc., to be the exclusive, global provider for Transposagen’s p53 and Bcrp TGEM Knockout Rat Models and associated downstream services utilizing these models

TOPICS:

Rational Selection of Patients for Clinical Trials

October 19, 2010 8:34 am | News | Comments

Horizon Discovery Ltd and Cylene Pharmaceuticals, Inc. will utilize Horizon's X-MANTM proprietary human isogenic cancer cell-lines to help identify potential patient benefit from Cylene's novel anticancer agent.

TOPICS:

Alzheimer's Drug Crosses the Blood-brain Barrier

October 19, 2010 8:22 am | News | Comments

A new study has found and tested in an animal model of Alzheimer’s disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.

TOPICS:
Advertisement

Tracking Timing of Egg Development

October 19, 2010 8:08 am | News | Comments

A research team has discovered molecular and cellular players in ovaries that control the timing of egg development in mammals.

TOPICS:

New Phases to Kinetex HPLC Column Line

October 19, 2010 7:55 am | Product Releases | Comments

Phenomenex Inc. announces the addition of two new phases in its Kinetex core-shell HPLC/UHPLC column family; Kinetex XB-C18 and Kinetex C8.

TOPICS:

Chemiluminescent Western Blotting Reagent

October 19, 2010 7:42 am | Product Releases | Comments

GE Healthcare has introduced Amersham ECL Prime, a highly sensitive reagent characterized by stable signal emission up to three hours after addition of the reagent, which allows for repeated exposures and makes it easier to process several blots in the same experimental run.

TOPICS:

Longer-lasting Options to Treat Drug Addiction

October 19, 2010 5:48 am | by Lauran Neergaard, AP Medical Writer | News | Comments

New treatments for addiction to heroin or narcotic painkillers promise longer-lasting relief that may remove some day-to-day uncertainty of care.

TOPICS:

FDA Panel Backs Anemia Drugs for Kidney Disease

October 19, 2010 5:42 am | by Matthew Perrone, AP Health Writer | News | Comments

FDA advisers said that patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

TOPICS:

Another Tylenol Recall for Moldy Smell

October 19, 2010 5:37 am | by Linda A. Johnson, AP Business Writer | News | Comments

Tylenol caplets are again being recalled by Johnson & Johnson after some consumers were sickened by ingesting the pills or smelling a musty or moldy odor on the bottles.

TOPICS:

J & J's 3Q Profit Up Slightly, Despite Lower Sales

October 19, 2010 5:33 am | by Linda A. Johnson, AP Business Writer | News | Comments

Health care giant Johnson & Johnson eked out a 2 percent profit increase in its third quarter, even though sales were down slightly, hurt by repeated product recalls and customer wariness.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading